These findings have led to speculation that FPS deficiency may be an important stimulus to thrombosis in patients with stroke of either known or unknown cause. We conducted this case-control study to test for an association between FPS deficiency and acute cerebral infarction among older (aged .40 years) individuals at risk for stroke.
Subjects and Methods
The case subjects were patients admitted to Columbia-Presbyterian Medical Center for acute cerebral infarction between January 1990 and June 1991. All were enrolled in the Northern Manhattan Stroke Study (NOMASS), a prospective epidemiological study of patients with ischemic stroke aged >39 years who reside in the five zip codes of northern Manhattan (10031, 10032, 10033, 10034, and 10040). FPS levels were measured as part of a standardized diagnostic evaluation in 94 of 187 NOMASS participants (50.3%) during the study period, primarily among those patients cared for by the investigators. Baseline demographic information and historical data were collected from the patient, family, and medical record. Stroke subtypes were classified according to the diagnostic criteria used in the Stroke Data Bank of the National Institute of Neurological Disorders and Stroke. 18 The 94 control subjects were patients admitted to the medicine and neurology services between January 1991 and June 1991, all of whom met the same age and geographic eligibility criteria used in NOMASS. Pa- tients were screened by use of lists of admitted patients provided by the hospital information system. For each patient a preliminary primary diagnosis was determined, and demographic and historical information were recorded by review of the chart. FPS levels were obtained in all patients shortly after admission, with the investigators blinded to the results until the conclusion of the study. After the data collection phase, a final primary diagnosis for each control patient was determined by review of the hospital discharge summary.
Since our goal was to test the strength of the association between FPS deficiency and stroke, patients with a history of cerebrovascular disease, past or present, were excluded from the control group. In order to avoid selection bias favoring acquired protein S-deficient states among the control subjects, we also excluded patients with a primary diagnosis that might involve or alter the coagulation system. These included thrombotic vascular diseases (myocardial infarction, unstable angina, deep venous thrombosis, pulmonary embolism, or symptomatic peripheral vascular disease), hematologic diseases (sickle cell disease, anemia, thrombocytopenia, or gastrointestinal bleeding), or medical conditions known to cause FPS deficiency19-22 (renal failure, hepatic failure, malignancy, infections, inflammatory diseases, and acquired immunodeficiency syndrome). Because secondary infections (such as pneumonia or urinary tract infection) are common after stroke, control patients who received treatment for infections unrelated to the primary diagnosis were not excluded. In addition, control patients with coagulopathy (defined as a prothrombin time >2.0 seconds over control) or proteinuria (defined as .3+ proteinuria on urinalysis) were excluded from the study.
Of 196 control patients initially screened, 166 were tested for FPS. Of these, 63 were excluded on the basis of a revised primary diagnosis and nine due to the presence of coagulopathy or proteinuria. Each group contained one patient who had received a single dose of warfarin before FPS testing.
To evaluate the comparability of the case and control groups with regard to acute phase reactants, we also retrospectively recorded the erythrocyte sedimentation rate (ESR) closest to the date of FPS testing when obtained.
The methodology used for FPS measurement has been described in detail previously.17 Briefly, venous blood samples were centrifuged, and the plasma was stored at -80°C until assayed. Laurell rocket immunoelectrophoresis was used to quantify the amount of FPS after separation and precipitation of bound protein S with polyethylene glycol 8000. Results were reported as a percentage of mean normal total protein S concentration. The normal range is 20-40% based on the plasma of 30 healthy subjects tested in our laboratory.
Informed written consent was obtained from all NOMASS participants, and informed verbal consent was obtained from all control subjects. Statistical comparisons were analyzed using the two-tailed t test for means and the X2 test for proportions. Odds ratios were calculated for case-control comparisons. Linear regression analysis (correlation coefficient) was performed using least-squares approximation. A value of p<0.05 was significant. ( Table 2) . No significant differences between the case and control groups in the frequency of FPS deficiency were found in subgroup comparisons based on age, sex, race, the presence of risk factors, time of FPS testing, and ESR.
FPS testing was performed an average of 1.7 days after admission (2.4 days after the onset of stroke) among the case patients, compared with 5.2 days after admission among the control patients (p<0.001). FPS deficiency was slightly more common in controls tested >6 days after admission (27%, 12 of 45) compared with those tested earlier (14%, seven of 49). Among the case patients, there was no relation between FPS and the interval from admission or the interval from stroke onset.
The frequency of FPS deficiency varied significantly with race in both groups, but not with age or sex ( Table  3) . Among all patients, FPS deficiency occurred in 34% of blacks and 13% of nonblacks (p=0.001). There was no relation between FPS levels and the presence of hypertension, diabetes, cardiovascular disease (history of myocardial infarction or angina), cigarette smoking, or heavy alcohol use in either group.
The mean+SEM ESR (normal range, 0-20 mm/hr) was 21.2+2.0 among the 84 case patients and 17.4±2.2 among the 59 control patients who were tested. A weak negative correlation between FPS and ESR was present among case patients (r=-0.09, p=0.41) and control patients (r=-0.15, p=0.26). Accordingly, FPS deficiency was slightly more common among patients with large elevations of the ESR (.30 mm/hr) in both groups (Table 3) .
Sufficient data were available to determine the stroke subtype in 91 of the 94 case patients. FPS deficiency occurred in 28.6% of patients with cardioembolic stroke (n=14), 23.1% of those with lacunar stroke (n=26), (n=35), and 12.5% of those with an atherosclerotic mechanism (n=16).
Discussion
Hematologic abnormalities represent the principal cause of ischemic stroke in approximately 1% of cases and are primarily identified in younger patients who lack evidence of other risk factors.23 However, the possible role of prothrombotic states acting in synergy with vascular disease in the pathogenesis of cerebrovascular occlusion has become increasingly recognized. In this scenario, abnormalities of the coagulation system may contribute to a substantial proportion of strokes by lowering the threshold of thrombogenesis in the presence of endovascular lesions.'723
Since hereditary FPS deficiency is rare,24 our previous finding of FPS deficiency in 20% of patients with acute stroke17 led us to speculate that acquired FPS deficiency may play a role in the pathogenesis of cerebral infarction in some patients. Because protein S forms an inactive complex with C4b-binding protein, an acute phase reactant, acquired FPS deficiency may result from a decrease in the ratio of FPS to bound protein S.25 FPS levels are reduced by this mechanism in pregnancy,26 malignancy,27 and oral contraceptive use28 and may contribute to the recognized risk of thromboembolism in these states.
The results of our study indicate that FPS deficiency (defined as <20% of normal total protein S) does not occur with increased frequency in adults with acute cerebral infarction when compared with hospitalized control patients. The study was designed to detect an odds ratio of .2.6 based on a power of 0.80 at the 0.05 (two-sided) level of significance. Although very low FPS (<15% of normal total protein S) occurred twice as frequently in patients with stroke, statistical confirmation of this finding would require a larger sample size.
Our results indicate that FPS deficiency is common among hospitalized patients, even in the absence of a recognized predisposing condition. Presumably, the majority of these deficiencies are acquired. Trends in our data favoring low FPS in patients with high ESR and in control subjects tested >6 days after admission support this interpretation. Because the normal range of our assay is based on the plasma of healthy ambulatory adults, we would expect to see a much lower rate of FPS deficiency in a group of age-and sex-matched nonhospitalized control subjects. Conversely, the frequency of FPS deficiency among patients with known predisposing conditions (e.g., sepsis, malignancy, renal failure) in our laboratory exceeds 40% (authors' unpublished results). Follow-up testing of acute stroke patients with FPS deficiency may provide evidence of a more sustained, and perhaps etiologically significant, abnormality.
We found that regardless of diagnosis, FPS deficiency occurred more frequently in blacks than nonblacks. Although the significance of this finding is unclear, it demonstrates that racial differences can exist in levels of coagulation factors, which may contribute to variations in the risk of stroke between ethnic groups. 29 We found no effect of sex on FPS, in contrast with selected series that have reported lower levels in women with16 and without28 stroke. Among our case patients, we found a higher frequency of cardioembolic stroke among FPS-17.1 % of those with infarct of undetermined cause deficient patients compared with nondeficient patients by guest on April 10, 2017 http://stroke.ahajournals.org/ Downloaded from (22% versus 14%), similar to our prior study (21% versus 8%, when limited to cases of cerebral infarction). 17 In both studies, this relation failed to reach statistical significance. However, the consistency of this finding may suggest an association between FPS deficiency and cardioembolic stroke.
Although our results do not support an association between FPS deficiency and ischemic stroke, a number of caveats must be emphasized. Our findings do not apply to FPS deficiency as a stroke risk factor in children and young adults. We did not take into account FPS activity, which can be measured using newly available functional assays. Although FPS levels and activity generally correlate well,'131924'30 this relation is more variable in acquired disorders.19,30 Thus, we cannot exclude a difference in the functional activity of FPS between the two groups. Finally, our data bear an uncertain relation to the prehospitalization protein S levels of the patients we studied. Antecedent FPS deficiency may have been more common in the patients with stroke.
Our case-control study suggests that acquired FPS deficiency is quite frequent among hospitalized patients but is not a major risk factor for ischemic stroke. Overall, if FPS deficiency does play a role in the pathogenesis of cerebral infarction, it may be limited to fewer patients with more severe degrees of FPS deficiency than had been initially suggested by our prior study.17 Future investigations will need to use other types of control groups, restrict measurements to the immediate period after hospitalization, explore differences by race/ethnicity and stroke subtype, and use functional assays.
